QbD Group announces acquisition of SciencePharma, strengthening global regulatory and quality expertise

Antwerp, Belgium / Warsaw, Poland – December 4, 2024 - QbD Group and SciencePharma have reached an agreement for QbD Group to acquire SciencePharma. The deal is expected to close by early 2025, pending antitrust clearance.

QbD Group, a privately held company offering comprehensive support to life sciences organizations, today announced the acquisition of SciencePharma. This strategic acquisition marks a significant milestone for QbD Group as it expands its international footprint, particularly in Poland and China. SciencePharma, known for its expertise in regulatory affairs and scientific consultancy will, as of January 2025, be part of QbD Group’s growing global network, enhancing both companies' ability to offer comprehensive solutions across the life sciences industry.

A shared vision for the future​

Bart Van Acker, founder and CEO of QbD Group, commented: "The acquisition of SciencePharma is a crucial step towards realizing our 'QbDream' by expanding through strategic acquisition. This move strengthens our presence in Eastern Europe and adds exceptional regulatory and product development expertise to our team. SciencePharma's established reputation in Poland and their extensive experience in international projects align perfectly with QbD Group's mission to offer a comprehensive range of services across the life sciences. From our first discussions, it was clear that QbD Group and SciencePharma share the same commitment to quality and innovation, and I’m confident that together we will accomplish great things."

Krzysztof Polkowski, CEO of SciencePharma, added: "This acquisition marks an exciting new phase for SciencePharma. As QbD Group integrates our team, we will be able to expand our global reach and continue delivering the high-quality regulatory and product development services that have defined our success. Our strong reputation in the industry will be further strengthened by the combined resources and expertise of QbD Group. I am confident that together, we will have an even greater impact on the life sciences sector."

SciencePharma’s team of 120 specialists will join QbD Group, further strengthening its core competencies in regulatory compliance, CMC services, and product development support. Following the planned transfer of shares, current owner Krzysztof Polkowski will step down from his role as CEO as of the beginning of 2025, with Monika Laskowska-Mirończuk taking over the daily management responsibilities.

Business continuity and future integration​

During the ongoing antitrust clearance process, there will be no immediate changes to operations, or the services offered by SciencePharma. Both companies are committed to maintaining a smooth transition with no disruption to clients, partners, and employees. "We want to reassure you that during the antitrust clearance process there will be no changes in the services you receive," said Van Acker. "You can expect the same level of support and dedication to your product lifecycle management that you have always received from SciencePharma."

Full integration of business operations will begin after the acquisition is finalized in early 2025. Customers and industry partners can look forward to more integrated and comprehensive services in the future, backed by QbD Group’s expanded resources and global reach. "With more resources and access to new markets, we will be even better equipped to meet your needs," added Van Acker.

About SciencePharma​

SciencePharma is a Polish company offering consulting and importing services for the pharmaceutical industry. Established in 2004, SciencePharma is a leader among Polish and foreign consulting companies, having successfully implemented national and international projects. Over the past decade, SciencePharma has prepared over 820 dossiers for medicinal products and excels in drug development projects, importation, and GMP/GDP compliance. With a diverse and experienced team, SciencePharma provides holistic support from early-stage development through clinical trials and product lifecycle management.